Thymic pathological examination of non-thymomatous myasthenia gravis patients: A pilot study for prediction of outcome.

  • Zeinab Peimani Mail Student Research Comittee, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Mohammad Amin Banihashemi Research Center for Traditional Medicine and History of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Niloofar Namazi Student Research Comittee, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Anahid Safari Department of Pharmacology, School of Medicine, Islamic Azad University, Kazeroon Branch, Kazeroon, Iran.
  • Ahmad Monabati Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
  • Mehra Mojallal Department of Pathology, Dena Hospital, Shiraz, Iran.
  • Afshin Borhani-Haghighi Health Policy Research Center, Shiraz University of Medical Sciences, Shiraz, Iran ; Department of Neurology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Keywords:
Antigens, Bcl-2-Associated X Protein, CD, Immunohistochemistry, Ki-67 Antigen, Myasthenia Gravis

Abstract

Background:  Myasthenia  gravis (MG) is an  autoimmune disorder   characterized   by  weakness   and   fatigability  of skeletal muscles. The aim of this study was to determine if pathological characteristics in non-thymomatous patients of MG would correlate with prognosis in a three year follow up.
Methods:  Patients  who  had  had  their  thymectomy   at least  three  years prior to  the  study  were  selected  from three  hospitals  and were followed for 3 years. Prognosis was assessed  via a devised  prognostic  scoring system. A pathological  exam of the specimen  from the thymus was done  using the following immunohistochemical markers: Bcl2, CD 3, CD 4, CD 5, CD 7, CD 10, CD 20cy, CD 23, CD 43, and Ki67.
Results: Fifteen patients  fulfilled the inclusion criteria and had a complete  follow-up. This included  3 males and 12 females with a mean age of 36.6 years at the start of the  study. The dominant  cell population was T lymphocytes. All T cells expressed  CD 3, CD 43, CD 5, and  Bcl-2. In  2 patient , CD 10 marker was positive in T cells. B cells were negative for activation marker CD 23, except for germinal center   dendritic   cells.  Due  to  the  limited  number   of patients  in the study, the power of the study would not allow for an analysis to assess correlation between histopathological data and prognosis.
Conclusion: This pilot study was an attempt to discover any prognostic indices from the histopathological examination  of the resected  thymic tissue in the patients with myasthenia gravis.

References

1. Rahimi Jaberi A, Manafi AR, Movahhedan H, Zeighami M, Honarparvaran S. The Epidemiologic, Clinical and Laboratory Findings of Patients with Myasthenia Gravis in Southern Iran. Galen Medical Journal 2012; 1(1): 20-3.
2. Drachman DB. Myasthenia gravis. N Engl J Med 1994; 330(25): 1797-810.
3. Mao ZF, Mo XA, Qin C, Lai YR, Olde Hartman TC. Course and prognosis of myasthenia gravis: a systematic review. Eur J Neurol 2010; 17(7): 913-21.
4. Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci 2003; 998: 413-23.
5. Nieto IP, Robledo JP, Pajuelo MC, Montes JA, Giron JG, Alonso JG, et al. Prognostic
How to Cite
1.
Peimani Z, Banihashemi MA, Namazi N, Safari A, Monabati A, Mojallal M, Borhani-Haghighi A. Thymic pathological examination of non-thymomatous myasthenia gravis patients: A pilot study for prediction of outcome. Curr J Neurol. 13(1):40-44.
Section
Special Articles